Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers
Objective: Implement depression screening using a validated instrument for people with Parkinson’s (PWP) as part of standard of care in the specialist movement disorders setting…Risk of Depression after Parkinson’s disease, stroke, multiple sclerosis, and migraine in an Iranian population
Objective: We aim to evaluate the prevalence of depression in disorders including multiple sclerosis (MS), Parkinson's disease (PD), migraine, and stroke. Also, we detect risk…Risk factors of sleep disordered breathing in Veterans with Parkinson’s disease.
Objective: To investigate factors associated with the risk of sleep disordered breathing (SDB) in Veterans with Parkinson's disease (PD). Background: Sleep disordered breathing is common…Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease
Objective: The aim of this study was to explore the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on…Suicidal ideation and suicide risk in Parkinson’s disease
Objective: To examine the prevalence of suicidal ideation and suicide risk in patients with Parkinson’s disease (PD) and to assess the relationship between suicidal ideation…Pain as a Risk Factor for Developing Depression among Patients with Parkinson’s Disease: A Systematic Review of 1426 patients
Objective: This systematic review aims mainly to investigate pain as an independent risk factor for developing depressive symptoms among patients with PD. Background: Parkinson's disease…Increased incidence of Functional movement disorders during COVID-19 pandemic
Objective: To assess the frequency of functional movement disorders (FMD) during the COVID-19 pandemic in comparison to the pre-pandemic period and to identify factors causing…Psilocybin therapy for depression and anxiety associated with Parkinson’s disease: a pilot study (NCT04932434)
Objective: To investigate the safety, tolerability, feasibility, and preliminary efficacy of moderate and high dose psilocybin treatment with psychotherapeutic support for comorbid Parkinson's disease (PD)…Habenula Volume in Mood Disorders in Parkinson’s Disease
Objective: To assess whether dysregulation of habenula (Hb) contributes to mood disorders in Parkinson’s disease (PD). Background: PD is often accompanied by mood disorders, such…Neuropsychiatric Symptoms in Early-Onset Parkinson’s Disease
Objective: To describe the neuropsychiatric symptoms of Early-Onset Parkinson’s Disease (EOPD) patients in an incident cohort study from 1991 to 2010 in Olmsted County, Minnesota…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 38
- Next Page »